Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is often
diagnosed at an advanced stage when most potentially curative therapies such as resection …

The treatment of hepatocellular carcinoma (HCC) remains a challenge, with 1-and 3-year
survival rates of 20% and 5%, respectively, and a median survival of 8 months. However, a …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors
worldwide. HCC is a complex process that is associated with several etiological factors …

Hepatocellular carcinoma (HCC) is a common malignancy and one of the leading causes of
cancer-related death. The biological process of HCC is complex, with multiple factors …

Hepatocellular carcinoma (HCC) is a highly prevalent, treatment-resistant malignancy with a
multifaceted molecular pathogenesis. Current evidence indicates that during …

Simple Summary Primary liver cancer, also known as Hepatocellular carcinoma (HCC), is
considered to be a major global health challenge. Due to delays in diagnosis at early …

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally.
The landscape of systemic therapy has recently changed, with six additional systemic …

Hepatocellular carcinoma (HCC) is characterized as a highly chemoresistant cancer with no
effective systemic therapy. Despite surgical or locoregional therapies, prognosis remains …

Hepatocellular carcinoma (HCC) remains a highly complex disease resistant to commonly
used chemotherapy and radiotherapy. As the sixth most common cancer worldwide with the …

Hepatocellular carcinoma (HCC) represents a unique challenge for physicians and patients.
There is no definitively curative treatment. Rather, many treatment and management …